Blood serum/blood plasma miRNA marker related to non-small cell lung cancer (SCLC) prognosis and application thereof

A non-small cell lung cancer, marker technology, applied in the direction of DNA/RNA fragment, recombinant DNA technology, microorganism determination/examination, etc., can solve the problem of poor prognosis of non-small cell lung cancer

Inactive Publication Date: 2010-02-03
NANJING MEDICAL UNIV
View PDF0 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Although the diagnosis level and treatment level of lung cancer have been continuously improved in recent years, the prognosis of non-small cell lung cancer is still poor, and the 5-year survival rate is less than 9% in developing countries and less than 15% in the United States. Forecasting and taking targeted and individualized treatment is the key to improving the treatment effect
[0007] However, there are currently no reports on th...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Blood serum/blood plasma miRNA marker related to non-small cell lung cancer (SCLC) prognosis and application thereof
  • Blood serum/blood plasma miRNA marker related to non-small cell lung cancer (SCLC) prognosis and application thereof
  • Blood serum/blood plasma miRNA marker related to non-small cell lung cancer (SCLC) prognosis and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0094] The collection of embodiment 1 sample and the arrangement of sample data

[0095] The inventor has collected a large number of serum samples from NSCLC patients from Jiangsu Cancer Hospital and the First Affiliated Hospital of Nanjing Medical University since July 2003. After sorting out the sample data, the inventor selected 303 samples that meet the following criteria Experimental samples for Solexa sequencing and subsequent series of qRT-PCR verification:

[0096] 1. New stage I-IIIa adenocarcinoma and squamous cell carcinoma;

[0097] 2. All underwent surgery and postoperative adjuvant chemotherapy;

[0098] 3. No surgery, radiotherapy and chemotherapy before blood collection, no preoperative radiotherapy and chemotherapy.

[0099] The demographic data, clinical data and follow-up data of these samples were collected systematically.

Embodiment 2

[0100] The Solexa sequencing experiment of microRNA in embodiment 2 serum / plasma

[0101] Among the above 303 eligible NSCLC patients, 30 surviving patients with a survival period of more than 30 months (34.6-61.8 months, average 49.54 months) at the last follow-up were selected as the "long-term survival" group, and another 30 patients were selected Dead patients with a survival time of less than 25 months (2.0-22.5 months, average 9.54 months) were taken as the "short-term survival" group. The clinical stage of the disease and smoking status were accurately matched between the two groups, and both underwent surgery and postoperative adjuvant chemotherapy. There was no difference in tissue types, and they were basically evenly comparable except for survival conditions and survival time (see Table 5). These two groups of people were used as exploratory samples to obtain related results through Solexa sequencing test. The specific steps are:

[0102] 1. Take 50ml of serum fro...

Embodiment 3

[0114] The qRT-PCR experiment of microRNA in embodiment 3 exploratory sample serum

[0115] According to the above-mentioned Solexa results, miRNAs that meet the following conditions are selected for further verification by qRT-PCR method: 1) miRNAs with a fold difference of up to 5 times in the two groups of NSCLC patients are used as serum biomarkers for preliminary screening in the present invention, 2) The copy number of these miRNAs in at least one group of NSCLC patients ("long-term survival" group or "short-term survival" group) is greater than 50 to improve detection efficiency. miRNAs meeting the above conditions include: miR-486, miR-22, miR-30d, miR-21, miR-26b, let7i, miR-378, miR-1, miR-206, miR-146b and miR-499. In addition, two let-7 family members (let-7a and let-7g) have only a two-fold difference, but these two miRNAs have been reported to be associated with lung cancer prognosis, so they were also included in our study. Primers for reverse transcription and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of genetic engineering and phymatology, in particular to a blood serum/blood plasma miRNA marker related to non-small cell lung cancer (SCLC) prognosis and an application thereof. The marker is one or more of miR-486, miR30d, miR-1 or miR-499 and can be used for preparing an auxiliary diagnostic reagent kit for the non-SCLC prognosis or a medicine for treating the SCLC.

Description

field of invention [0001] The invention belongs to the fields of genetic engineering and oncology, and relates to a serum / plasma miRNA marker related to the prognosis of non-small cell lung cancer and an application thereof. Background technique [0002] Lung cancer is the most common malignant tumor in humans. The main pathological types of lung cancer include non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Among them, non-small cell lung cancer accounts for 80-85% of the total number of lung cancers, ranking first in the world. It ranks first in the incidence and mortality of tumors in the world. At present, there are more than 1 million new lung cancer patients worldwide every year. In 2002, there were 1.35 million new cases of lung cancer in the world, and 1.18 million people died of lung cancer. In recent years, the incidence and death of lung cancer in my country have been on the rise. In 2002, the incidence of lung cancer in my country was 42.4 / ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/11C12Q1/68A61K48/00A61P35/00A61P11/00C12N15/113
Inventor 沈洪兵胡志斌张承宇陈熹靳光付曾科马红霞董静张鸣凤
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap